DYRK1A as a novel target for glioblastoma therapies

Johns, Terry (Primary Chief Investigator (PCI))
Kassiou, Michael (Chief Investigator (CI))

Hudson Institute - Centre for Cancer Research

Project: Research

1 Article

1 results

2017

Structural Optimization and Pharmacological Evaluation of Inhibitors Targeting Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases (DYRK) and CDC-like kinases (CLK) in Glioblastoma
Zhou, Q., Phoa, A. F., Abbassi, R. H., Hoque, M., Reekie, T. A., Font, J. S., Ryan, R. M., Stringer, B. W., Day, B. W., Johns, T. G., Munoz, L. & Kassiou, M., 9 Mar 2017, In: Journal of Medicinal Chemistry. 60, 5, p. 2052-2070 19 p.
Research output: Contribution to journal › Article › Research › peer-review

48 Citations (Scopus)